Month: February 2021

CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) — Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its fourth-quarter 2020 financial results and provided a business update.“2020 was an important year for Constellation Pharmaceuticals, marked by several presentations of strong data from our MANIFEST clinical trial for pelabresib (formerly CPI-0610), including our oral presentations at the ASH Annual Meeting,” said Jigar Raythatha, President and Chief Executive Officer of Constellation Pharmaceuticals. “We are executing on our recently launched Phase 3 trial, MANIFEST-2 and believe pelabresib has the potential to transform the standard of care in myelofibrosis. We also continue to advance our pipeline of product...

NEW YORK and SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) — Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that initial clinical data from the Phase 1 portion of its Phase 1/2 monotherapy trial of ZN-c3, the Company’s WEE1 inhibitor, in advanced solid tumors has been selected for presentation at the upcoming virtual American Association for Cancer Research (AACR) Annual Meeting 2021. AACR is being held April 10-15 and May 17-21.About ZN-c3ZN-c3 is an oral inhibitor of WEE1 in development for the treatment of advanced solid tumors. The inhibition of WEE1, a DNA damage response protein, aims to generate sufficient DNA damage in cancer cells, causing cell death,...

CALGARY, Alberta, Feb. 24, 2021 (GLOBE NEWSWIRE) — Sugarbud Craft Growers Corp. (TSXV: SUGR, SUGR.WT, SUGR.WS, SUGR.DB) (“Sugarbud” or the “Company“) is pleased to announce that it has received an initial purchase order for the Company’s Craft Cannabis products and will begin shipping to the British Columbia Liquor Distribution Branch (“LDB“) in early March 2021.The LDB is responsible for the wholesale distribution of non-medical cannabis to private retailers and is the public retailer of non-medical cannabis throughout the province, under the brand BC Cannabis Stores (“BCCS“).The Company expects these first shipments to the LDB will be available online at BCCannabisStores.com, Provincial BC Cannabis Stores and private retailers in March 2021.“We are delighted that Sugarbud’s...

VANCOUVER, British Columbia, Feb. 24, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Hunter Technology Corp. (TSX-V: HOC; OTCQB: HOILF; WKN: A2QEYH, FSE: RWPM, ISIN: CA4457371090) (“Hunter” or the “Company”) is pleased to provide an update on the integration and development of its FinFabrik core assets.On December 31, 2020, Hunter acquired 100% of the issued and outstanding shares of FinFabrik Limited of Hong Kong for consideration of USD $11,149,182, paid in cash and common shares of Hunter, for the purpose of utilizing FinFabrik assets to accelerate the development to commercialization of its OilEx and OilExchange platforms. For additional information regarding FinFabrik or the transaction, please see Hunter’s news release dated December 14, 2020, which is available on SEDAR at www.SEDAR.com. FinFabrik’s assets included...

WATERTOWN, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the following upcoming March investor conferences:Cowen 41st Annual Health Care Conference on Wednesday, March 3, 2021 at 11:40 a.m. ETGuggenheim Targeted Protein Degradation Day panel discussion on Tuesday, March 16, 2021 at 10:30 a.m. ETA live webcast of each event can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.c4therapeutics.com. Replays of the webcasts will be archived on the C4T website for at least two weeks following each presentation.About C4 TherapeuticsC4 Therapeutics...

CHARLOTTE, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) — Driven Brands Holdings Inc. (NASDAQ: DRVN) (“Driven Brands”) will release fourth quarter and fiscal year 2020 financial results before the market opens on March 10, 2021. Following the release, Driven Brands will host a conference call at 9:00 a.m. ET to review the financial results.The conference call will be available via live webcast on Driven Brands’ Investor Relations webpage at investors.drivenbrands.com. A webcast replay of the call will be available later the same day until April 27, 2021.About Driven BrandsDriven Brands™, headquartered in Charlotte, NC, is the largest automotive services company in North America, providing a range of consumer and commercial automotive needs, including paint, collision, glass, vehicle repair, oil change, maintenance and car wash. Driven Brands...

SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, tipifarnib, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma (HNSCC) with variant allele frequency ≥ 20% after disease progression on platinum-based chemotherapy. Tipifarnib is currently being evaluated in an ongoing registration-directed clinical trial (AIM-HN) in this indication of high unmet need.HNSCC is the seventh most common cancer worldwide, accounting for more than 885,000 new cases each year. Despite recent treatment...

BELGRADE, Mont., Feb. 24, 2021 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2020.Fourth Quarter 2020 Financial Highlights:Revenue for the fourth quarter of 2020 totaled $14.0 million, compared to $17.0 million for the prior-year periodOperating expenses in the fourth quarter of 2020 totaled $8.7 million, compared to $11.7 million for the prior-year periodIncome from operations totaled $0.2 million, compared to an operating loss of $0.3 million for the prior-year periodNet loss incurred in the fourth quarter of 2020 totaled $0.7 million, compared to a net loss of $1.6 million for the prior-year periodNon-GAAP...